The safety of available treatments for chronic constipation

Expert Opinion on Drug Safety

Volumn 16, Issue 11, 2017, Pages 1243-1253

  Serrano Falcón, Blanca ^a   Rey, Enrique ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

adverse effects; Constipation; laxatives; linaclotide; lubiprostone; prucalopride

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BILE ACID SEQUESTRANT; CARBAMAZEPINE; CISAPRIDE; CYANOCOBALAMIN; DICOUMAROL; ELOXIBIBAT; ENEMA; GLYCEROL; LAXATIVE; LINACLOTIDE; LITHIUM; LUBIPROSTONE; MOLASSES; PHENOLPHTHALEIN; PLECANATIDE; PRUCALOPRIDE; SODIUM DIHYDROGEN PHOSPHATE; TEGASEROD; THYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALLERGY; BLOATING; BREAST FEEDING; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC CONSTIPATION; COLON CANCER; COLON MOTILITY; DEHYDRATION; DIARRHEA; DRUG DEPENDENCE; DRUG EFFECT; DRUG SAFETY; FAINTNESS; FECES INCONTINENCE; FEVER; FLATULENCE; HEADACHE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERNATREMIA; HYPERPHOSPHATEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; MELANOSIS; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PNEUMONIA; PREGNANCY; QT PROLONGATION; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; TACHYPHYLAXIS; UNSTABLE ANGINA PECTORIS; ANIMAL; CHRONIC DISEASE; CONSTIPATION; PATIENT SATISFACTION; QUALITY OF LIFE; TIME FACTOR;

ANIMALS; CHRONIC DISEASE; CONSTIPATION; HUMANS; LAXATIVES; PATIENT SATISFACTION; QUALITY OF LIFE; TIME FACTORS;

EID: 85031119098     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1361402     Document Type: Review

References (132)

1. Bharucha AE, Dorn SD, Lembo A, et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211–217.
2. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016. Doi: 10.1053/j.gastro.2016.02.031.
3. Mugie SM, Benninga MA, Di Lorenzo C., Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol. 2011;25(1):3–18.
4. Johanson JF, Kralstein J., Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599–608.
5. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol. 2014;109(6):876–884.
6. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25(Suppl):B:11b-5b.
7. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96(11):3130–3137.
8. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33(6):818–824.
9. Emmanuel A, Quigley EM, Simren M, Feng Y, Muller-Lissner S, Urbain D, et al. Factors affecting satisfaction with treatment in European women with chronic constipation: an internet survey. United European Gastroenterol J. 2013;1(5):375–384.
10. Muller-Lissner S, Tack J, Feng Y, et al. Levels of satisfaction with current chronic constipation treatment options in Europe - an internet survey. Aliment Pharmacol Ther. 2013;37(1):137–145.
11. Rey E, Barcelo M, Jimenez Cebrian MJ, et al. A nation-wide study of prevalence and risk factors for fecal impaction in nursing homes. PloS One. 2014;9(8):e105281.
12. Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study. BMC Gastroenterol. 2017;17(1):11.
13. Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol: WJG. 2012;18(36):4994–5013.
14. Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation–a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710.
15. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Safety. 1994;10(1):47–65.
16. Muller-Lissner S. What has happened to the cathartic colon? Gut. 1996;39(3):486–488.
17. Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. Pharmacology. 1993;47(Suppl 1):138–145.
18. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209–218.
19. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46(4):522–526.
20. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci. 1996;41(8):1636–1642.
21. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897–903.
22. Kamm, MA, Mueller-Lissner SA, Wald A, et al. Stimulant laxatives are effective in chronic constipation: multi-center, 4-week, double-blind, randomized, placebo-controlled trial of bisacodyl. Gastroenterology. 2010;138(Suppl 1):S228.
23. Basilisco G, Marino B, Passerini L, et al. Abdominal distension after colonic lactulose fermentation recorded by a new extensometer. Neurogastroenterol Motil. 2003;15(4):427–433.
24. Lederle FA, Busch DL, Mattox KM, et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am J Med. 1990;89(5):597–601.
25. Di Palma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol. 2007;102(9):1964–1971.
26. Di Palma JA, Cleveland MV, McGowan J, et al. An open-label study of chronic polyethylene glycol laxative use in chronic constipation. Aliment Pharmacol Ther. 2007;25(6):703–708.
27. Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999;44(2):226–230.
28. Minguez M, Lopez Higueras A, Judez J. Use of polyethylene glycol in functional constipation and fecal impaction. Rev Esp Enferm Dig. 2016;108(12):790–806.
29. Nagarajan N, Morden A, Bischof D, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27(9):1002–1010.
30. Cheskin LJ, Kamal N, Crowell MD, et al. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc. 1995;43(6):666–669.
31. Fenn GC, Wilkinson PD, Lee CE, et al. A general practice study of the efficacy of regulan in functional constipation. Br J Clin Pract. 1986;40(5):192–197.
32. Ashraf W, Park F, Lof J, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9(6):639–647.
33. Wang HJ, Liang XM, Yu ZL, et al. Controlled comparison of low-dose polyethylene glycol 3350 plus electrolytes with ispaghula husk in the treatment of adults with chronic functional constipation. Clin Drug Investig. 2004;24(10):569–576.
34. Passmore AP, Wilson-Davies K, Stoker C, et al. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ. 1993;307(6907):769–771.
35. Perkin JM. Constipation in childhood: a controlled comparison between lactulose and standardized senna. Curr Med Res Opin. 1977;4:540–543.
36. Pare P, Fedorak RN. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Can J Gastroenterol Hepatol. 2014;28(10):549–557.
37. Obokhare I. Fecal impaction: a cause for concern? Clin Colon Rectal Surg. 2012;25(1):53–58.
38. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001;44(8):1201–1209.
39. Serrano Falcon B, Alvarez Sanchez A, Diaz-Rubio M, et al. Prevalence and factors associated with faecal impaction in the Spanish old population. Age Ageing. 2016.
40. Katelaris P, Naganathan V, Liu K, et al. Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis. BMC Gastroenterol. 2016;16:42.
41. Szojda MM, Mulder CJ, Felt-Bersma RJ. Differences in taste between two polyethylene glycol preparations. J Gastrointestin Liver Dis. 2007;16(4):379–381.
42. Di Palma JA, Smith JR, Cleveland M. Overnight efficacy of polyethylene glycol laxative. Am J Gastroenterol. 2002;97(7):1776–1779.
43. Weng YM, Chen SY, Chen HC, et al. Hypermagnesemia in a constipated female. J Emerg Med. 2013;44(1):e57–60.
44. [Cited 20 Apr 2017]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm380757.htm). 04 Oct 2017.
45. Nyberg C, Hendel J, Nielsen OH. The safety of osmotically acting cathartics in colonic cleansing. Nat Reviews Gastroenterol Hepatology. 2010;7(10):557–564.
46. Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. Dig Dis Sci. 2005;50(7):1319–1323.
47. Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med. 2003;349(10):1006–1007.
48. Harrison NM, Hjelkrem MC. Bowel cleansing before colonoscopy: balancing efficacy, safety, cost and patient tolerance. World J Gastrointest Endosc. 2016;8(1):4–12.
49. Yoon HE, Kim YW, Ha KS, et al. Hypermagnesemia accompanied with colonic perforation in a hemodialysis patient. Yonsei Med J. 2013;54(3):797–800.
50. Tatsumi H, Masuda Y, Imaizumi H, et al. A case of cardiopulmonary arrest caused by laxatives-induced hypermagnesemia in a patient with anorexia nervosa and chronic renal failure. J Anesth. 2011;25(6):935–938.
51. Khairi T, Amer S, Spitalewitz S, et al. Severe symptomatic hypermagnesemia associated with over-the-counter laxatives in a patient with renal failure and sigmoid volvulus. Case Reports Nephrol. 2014;2014:560746.
52. Karahan MA, Kucuk A, Buyukfirat E, et al. Acute respiratory and renal failure due to hypermagnesemia, induced by counter laxatives in an elderly man. J Clin Diagn Res. 2015;9(12):Ul01.
53. Tapia H, Mora C, Navarro JF. [Magnesium in chronic kidney disease]. Nefrologia. 2007;27(6):674–680.
54. Izdes S, Kesimci E, Kanbak O. Paralytic ileus as a complication of iatrogenic hypermagnesaemia without renal dysfunction. Anaesth Intensive Care. 2008;36(1):124.
55. Schorr M, Miller KK. The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Reviews Endocrinol. 2017;13(3):174–186.
56. Weir MA, Fleet JL, Vinden C, et al. Hyponatremia and sodium picosulfate bowel preparations in older adults. Am J Gastroenterol. 2014;109(5):686–694.
57. Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386–389.
58. Freeman HJ. “Melanosis” in the small and large intestine. World J Gastroenterol: WJG. 2008;14(27):4296–4299.
59. Siegers CP, Von Hertzberg-Lottin E, Otte M, et al. Anthranoid laxative abuse–a risk for colorectal cancer? Gut. 1993;34(8):1099–1101.
60. Koskela E, Kulju T, Collan Y. Melanosis coli prevalence, distribution, histologic features 200 consecutive autopsies at Kuopio University Central Hospital. Diseases Colon Rectum. 1989;32(3):235–239.
61. Walker NI, Smith MM, Smithers BM. Ultrastructure of human melanosis coli with reference to its pathogenesis. Pathology. 1993;25(2):120–123.
62. Toyoda K, Nishikawa A, Furukawa F, et al. Cell proliferation induced by laxatives and related compounds in the rat intestine. Cancer Lett. 1994;83(1–2):43–49.
63. van Gorkom BA, Timmer-Bosscha H, de Jong S, van der Kolk DM, Kleibeuker JH, de Vries EG. Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1. Br J Cancer. 2002;86(9):1494–1500.
64. Nishikawa A, Kase Y, Hayakawa T, et al. Enhancement of cell proliferation and prostaglandin biosynthesis by 1,8-dihydroxyanthraquinone in the rat large intestine. Carcinogenesis. 1997;18(6):1259–1263.
65. Kune GA. Laxative use not a risk for colorectal cancer: data from the Melbourne Colorectal Cancer Study. Z Gastroenterol. 1993;31(2):140–143.
66. Nakamura GJ, Schneiderman LJ, Klauber MR. Colorectal cancer and bowel habits. Cancer. 1984;54(7):1475–1477.
67. Roberts MC, Millikan RC, Galanko JA, et al. Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol. 2003;98(4):857–864.
68. Patel PM, Selby PJ, Deacon J, et al. Anthraquinone laxatives and human cancer: an association in one case. Postgrad Med J. 1989;65(762):216–217.
69. Khilnani GC, Hadda V. Lipoid pneumonia: an uncommon entity. Indian J Med Sci. 2009;63(10):474–480.
70. Meltzer E, Guranda L, Vassilenko L, et al. Lipoid pneumonia: a preventable complication. Isr Med Assoc J: IMAJ. 2006;8(1):33–35.
71. Cornacchia DJ, Snyder CH, Dupont DC, et al. Exogenous lipoid pneumonia. J Am Osteopath Assoc. 1989;89(5):659–663.
72. Meltzer E, Guranda L, Perelman M, et al. Lipoid pneumonia: a preventable form of drug-induced lung injury. Eur J Intern Med. 2005;16(8):615–617.
73. Midulla F, Strappini PM, Ascoli V, et al. Bronchoalveolar lavage cell analysis in a child with chronic lipid pneumonia. Eur Respir J. 1998;11(1):239–242.
74. Suhonen R, Kantola I, Bjorksten F. Anaphylactic shock due to ingestion of psyllium laxative. Allergy. 1983;38(5):363–365.
75. Zaloga GP, Hierlwimmer UR, Engler RJ. Anaphylaxis following psyllium ingestion. J Allergy Clin Immunol. 1984;74(1):79–80.
76. Vaswani SK, Hamilton RG, Valentine MD, et al. Psyllium laxative-induced anaphylaxis, asthma, and rhinitis. Allergy. 1996;51(4):266–268.
77. Sussman GL, Dorian W. Psyllium anaphylaxis. Allergy Proc. 1990;11(5):241–242.
78. Seggev JS, Ohta K, Tipton WR. IgE mediated anaphylaxis due to a psyllium-containing drug. Ann Allergy. 1984;53(4):325–326.
79. Lantner RR, Espiritu BR, Zumerchik P, et al. Anaphylaxis following ingestion of a psyllium-containing cereal. JAMA: Journal Am Med Assoc. 1990;264(19):2534–2536.
80. Khalili B, Bardana EJ, Jr., Yunginger JW. Psyllium-associated anaphylaxis and death: a case report and review of the literature. Ann Allergy Asthma Immunol. 2003;91(6):579–584.
81. James JM, Cooke SK, Barnett A, et al. Anaphylactic reactions to a psyllium-containing cereal. J Allergy Clin Immunol. 1991;88(3 Pt 1):402–408.
82. Drake CL, Moses ES, Tandberg D. Systemic anaphylaxis after ingestion of a psyllium-containing breakfast cereal. Am J Emerg Med. 1991;9(5):449–451.
83. Lee SH, Hwang SH, Park JS, et al. Anaphylaxis to polyethylene glycol (Colyte(R)) in a patient with diverticulitis. J Korean Med Sci. 2016;31(10):1662–1663.
84. Soto Mera T, Filgueira JF, Villamil E. Linseed: a dangerous antigen. Rev Esp Alergol Inmunol Clín. 1998;13(6):362–363.
85. Pahor M, Guralnik JM, Chrischilles EA, et al. Use of laxative medication in older persons and associations with low serum albumin. J Am Geriatr Soc. 1994;42(1):50–56.
86. Beuers U, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet. 1991;337(8737):372–373.
87. Sipe HJ, Jr., Corbett JT, Mason RP. In vitro free radical metabolism of phenolphthalein by peroxidases. Drug Metab Dispos. 1997;25(4):468–480.
88. Cooper GS, Longnecker MP, Sandler DP, et al. Risk of ovarian cancer in relation to use of phenolphthalein-containing laxatives. Br J Cancer. 2000;83(3):404–406.
89. Cooper GS, Longnecker MP, Peters RK. Ovarian cancer risk and use of phenolphthalein-containing laxatives. Pharmacoepidemiol Drug Saf. 2004;13(1):35–39.
90. Aboumarzouk OM, T A, R A, et al. Cisapride for intestinal constipation. Cochrane Database Syst Rev. 2011;(1):Cd007780.
91. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745–767.
92. Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci. 2016;61(8):2357–2372.
93. Muller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22(9):991–8, e255.
94. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21(12):1256–e117.
95. Mozaffari S, Nikfar S, Abdollahi M. Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients. Arch Med Sci. 2014;10(1):10–18.
96. Lembo AJ, Cremonini F, Meyers N, et al. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther. 2010;31(9):979–990.
97. Layer P, Stanghellini V. Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39(4):371–384.
98. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6):1877–86.e2.
99. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702–1712.
100. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-24; quiz p.25.
101. Rey E, Mearin F, Alcedo J, et al. Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report. Adv Ther. 2017;34(3):587–598.
102. Izzy M, Malieckal A, Little E, et al. Review of efficacy and safety of laxatives use in geriatrics. World J Gastrointest Pharmacol Ther. 2016;7(2):334–342.
103. Miner PB, Jr., Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613–621.
104. Methylnaltrexone: MNTX. Drugs R D. 2006;7(6):374–378.
105. Viscusi ER, Barrett AC, Paterson C, et al. Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis. Reg Anesth Pain Med. 2016;41(1):93–98.
106. Corsetti M, Tack J. Naloxegol, a new drug for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2015;16(3):399–406.
107. Poulsen JL, Brock C, Olesen AE, et al. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–358.
108. Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. Expert Opin Pharmacother. 2015;16(4):515–532.
109. Mosinska P, Fichna J, Storr M. Inhibition of ileal bile acid transporter: an emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol: WJG. 2015;21(24):7436–7442.
110. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol. 2012;5(4):233–247.
111. Christensen P, Krogh K, Buntzen S, et al. Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum. 2009;52(2):286–292.
112. Alessi CA, Henderson CT. Constipation and fecal impaction in the long-term care patient. Clin Geriatr Med. 1988;4(3):571–588.
113. Bowers B. Evaluating the evidence for administering phosphate enemas. Br J Nurs. 2006;15(7):378–381.
114. Mendoza J, Legido J, Rubio S, et al. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther. 2007;26(1):9–20.
115. Sedaba B, Azanza JR, Campanero MA, et al. Effects of a 250-mL enema containing sodium phosphate on electrolyte concentrations in healthy volunteers: an open-label, randomized, controlled, two-period, crossover clinical trial. Curr Ther Res Clin Exp. 2006;67(5):334–349.
116. de Giorgio R, Ruggeri E, Stanghellini V, et al. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol. 2015;15(1):130.
117. Vilke GM, DeMers G, Patel N, et al. Safety and efficacy of milk and molasses enemas in the emergency department. J Emerg Med. 2015;48(6):667–670.
118. Guideline on the evaluation of medicinal products for the treatment of chronic constipation. European Med Agency. 2014. [Cited 30 Jul 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2009/12/WC500018443.pdf.
119. Fong SY, Gao Q, Zuo Z. Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review. Evid Based Complement Alternat Med. 2013;2013:898261.
120. Community herbal monograph on psyllium seed European Medicines Agency evaluation of medicines for human use. 2005
121. Wang MT, Li IH, Lee WJ, et al. Exposure to sennoside-digoxin interaction and risk of digoxin toxicity: a population-based nested case-control study. Eur J Heart Fail. 2011;13(11):1238–1243.
122. Tolman KG, Hammar S, Sannella JJ. Possible hepatotoxicity of doxidan. Ann Intern Med. 1976;84(3):290–292.
123. Chey W, Shiff S, Schneier H, et al. Two years on linaclotide: tolerability and treatment satisfaction in IBS-C patients with and without diarrhea. Am J Gastroenterol. 2014;109(2):1111.
124. Roerig JL, Steffen KJ, Mitchell JE, et al. Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010;70(12):1487–1503.
125. Mearin F, Ciriza C, Minguez M, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363.
126. Neri I, Blasi I, Castro P, et al. Polyethylene glycol electrolyte solution (Isocolan) for constipation during pregnancy: an observational open-label study. J Midwifery Womens Health. 2004;49(4):355–358.
127. Nardulli G, Limongi F, Sue G, et al. [Use of polyethylene glycol in the treatment of puerperal constipation]. Gen. 1995;49(3):224–226.
128. Rungsiprakarn P, Laopaiboon M, Sangkomkamhang US, et al. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev. 2015;9:Cd011448.
129. [Cited 2017 Apr 16]. Available from: https://www.aemps.gob.es/cima/dochtml/ft/33581/FichaTecnica_33581.html. 04/16/2017.
130. [Cited 2017 Apr 16]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf. 04/16/2017.
131. Li Z, Pergolizzi JV, Huttner RP, et al. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. J Clin Pharm Ther. 2015;40(6):615–619.
132. [Cited 2017 Apr 20]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAREPAR_-_Product_Information/human/000870/WC500050562.pdf. 07/12/2017.